SynthesisObesity surgery2026
Effectiveness of Metabolic and Bariatric Surgery for Patients with Obesity and Asthma: A Systematic Review and Meta-Analysis.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a modifiable risk factor for asthma worldwide and is associated with poor asthma control. Weight loss is an effective intervention for patients with obesity and asthma; however, a consistent association between metabolic bariatric surgery (MBS) and asthma in patients with obesity is lacking. To assess the effects of MBS in patients with obesity and asthma, we conducted a meta-analysis of data from inception to February 2026. Thirty-three observational studies including 3731 patients were analyzed. A total of 47% of patients achieved discontinuation of asthma medication (95% CI, 0.38-0.56; p < 0.05), and 58% of patients achieved clinical asthma remission (95% CI, 0.45-0.70; p < 0.05). Additionally, MBS was associated with an 8.5% increase in forced expiratory volume in one second (FEV1) (95% CI, 4.5-12.6; p < 0.05) and a 9.4% increase in forced vital capacity (FVC) (95% CI, 6.3-12.6; p < 0.05). This evidence suggests that MBS results in clinical remission of asthma and improvement in pulmonary function in patients with obesity and asthma. KEY POINTS: •MBS can alleviate clinical asthma in patients with obesity. •MBS can improve FEV1 in patients with obesity and asthma. •MBS can improve FVC in patients with obesity and asthma.
Indexed as
Identifiers
42154213What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.